| Title |
Current Status: Site-Specific Antibody Drug Conjugates
|
|---|---|
| Published in |
Journal of Clinical Immunology, March 2016
|
| DOI | 10.1007/s10875-016-0265-6 |
| Pubmed ID | |
| Authors |
Dominik Schumacher, Christian P. R. Hackenberger, Heinrich Leonhardt, Jonas Helma |
| Abstract |
Antibody drug conjugates (ADCs), a promising class of cancer biopharmaceuticals, combine the specificity of therapeutic antibodies with the pharmacological potency of chemical, cytotoxic drugs. Ever since the first ADCs on the market, a plethora of novel ADC technologies has emerged, covering as diverse aspects as antibody engineering, chemical linker optimization and novel conjugation strategies, together aiming at constantly widening the therapeutic window for ADCs. This review primarily focuses on novel chemical and biotechnological strategies for the site-directed attachment of drugs that are currently validated for 2nd generation ADCs to promote conjugate homogeneity and overall stability. |
Mendeley readers
The data shown below were compiled from readership statistics for 241 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | <1% |
| United States | 1 | <1% |
| China | 1 | <1% |
| Belgium | 1 | <1% |
| Unknown | 237 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 50 | 21% |
| Researcher | 46 | 19% |
| Student > Master | 27 | 11% |
| Student > Bachelor | 26 | 11% |
| Other | 17 | 7% |
| Other | 26 | 11% |
| Unknown | 49 | 20% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 60 | 25% |
| Chemistry | 50 | 21% |
| Agricultural and Biological Sciences | 28 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 14 | 6% |
| Medicine and Dentistry | 12 | 5% |
| Other | 27 | 11% |
| Unknown | 50 | 21% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 13 February 2024.
All research outputs
#3,162,978
of 23,056,273 outputs
Outputs from Journal of Clinical Immunology
#163
of 1,577 outputs
Outputs of similar age
#52,957
of 300,722 outputs
Outputs of similar age from Journal of Clinical Immunology
#2
of 54 outputs
Altmetric has tracked 23,056,273 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,577 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.4. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 300,722 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 82% of its contemporaries.
We're also able to compare this research output to 54 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 96% of its contemporaries.